<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Severe <z:hpo ids='HP_0005549'>congenital neutropenia</z:hpo> <z:chebi fb="0" ids="29425">(SCN)</z:chebi> is an inborn disorder of granulopoiesis </plain></SENT>
<SENT sid="1" pm="."><plain>Like most other <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo> syndromes, it is associated with a marked propensity to transform into a <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) or <z:hpo ids='HP_0002488'>acute leukemia</z:hpo>, with a cumulative rate of transformation to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:hpo ids='HP_0001909'>leukemia</z:hpo> that exceeds 20% </plain></SENT>
<SENT sid="2" pm="."><plain>The genetic (and/or epigenetic) changes that contribute to <z:e sem="disease" ids="C1608408" disease_type="Neoplastic Process" abbrv="">malignant transformation</z:e> in <z:chebi fb="0" ids="18022">SCN</z:chebi> are largely unknown </plain></SENT>
<SENT sid="3" pm="."><plain>In this study, we performed mutational profiling of 14 genes previously implicated in <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">leukemogenesis</z:e> using 14 MDS/<z:hpo ids='HP_0001909'>leukemia</z:hpo> samples from patients with <z:chebi fb="0" ids="18022">SCN </z:chebi></plain></SENT>
<SENT sid="4" pm="."><plain>We used high-throughput exon-based resequencing of whole-genome-amplified genomic DNA with a semiautomated method to detect mutations </plain></SENT>
<SENT sid="5" pm="."><plain>The sensitivity and specificity of the sequencing pipeline was validated by determining the frequency of mutations in these 14 genes using 188 de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> samples </plain></SENT>
<SENT sid="6" pm="."><plain>As expected, mutations of tyrosine kinase genes (FLT3, KIT, and JAK2) were common in de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, with a cumulative frequency of 30% </plain></SENT>
<SENT sid="7" pm="."><plain>In contrast, no mutations in these genes were detected in the <z:chebi fb="0" ids="18022">SCN</z:chebi> samples; instead, mutations of CSF3R, encoding the G-CSF receptor, were common </plain></SENT>
<SENT sid="8" pm="."><plain>These data support the hypothesis that mutations of CSF3R may provide the "activated tyrosine kinase signal" that is thought to be important for <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">leukemogenesis</z:e> </plain></SENT>
</text></document>